Sunstone Therapies

09/09/2025

Sunstone is currently enrolling for the REKINDLE Study that explores a potential new approach for emotional distress linked to a life-changing illness.

To learn more about this study, click here:

Explore RE104 for Adjustment Disorder in Serious Illness and its potential benefits. Learn more about this exciting study.

09/03/2025

For patients with cancer and depression, therapy isn’t just about symptom relief — it’s about finding meaning. Our latest research, published in Psychedelic Medicine, explores how Meaning-Centered Psychotherapy can optimize psilocybin treatment for people with advanced cancer.

In collaboration with researchers at Memorial Sloan Kettering, our CEO & PI Dr. Manish Agrawal and Sunstone Therapist Betsy Jenkins, LCPC, have published a new article introducing a 5-session model: Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy (MCP-PSIL).

This work, based on insights from patients and therapists, aims to optimize the therapeutic experience for those with advanced cancer and depression. We believe this model can help maximize meaning-making opportunities and reduce distress throughout their treatment journey.

Click here to read the full study: https://www.sunstonetherapies.com/research-paper-highlights-meaning-centered-psychotherapy-for-psilocybin-therapy-in-cancer-care/

08/29/2025

Sunstone is enrolling for the ELUMINA trial, a study researching an investigational treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive Disorder (TRD). The investigational study medicine, called VLS-01 Buccal Film, is similar to DMT.

Learn more about this study and see if you or someone you may know may qualify: https://www.sunstonetherapies.com/science/clinical-trials/a-study-to-assess-the-efficacy-safety-and-tolerability-of-vls-01-buccal-film-compared-to-placebo-in-patients-with-treatment-resistant-depression-trd/

08/21/2025

Our study on the Long-Term Benefits of Single-Dose Psilocybin for Cancer-Related Depression, published earlier this summer in 📗 Cancer, American Cancer Society Journals, continues to spark important conversations. Sharing it again for those who may have missed it.

The results? Lasting improvements in depression and anxiety — from just one 25 mg dose with psychological support.

This research, led by our CEO & Principal Investigator Dr. Manish Agrawal, highlights the promise of psychedelic-assisted therapy to address depression and the importance of long-term follow-up in clinical trials.

We’re committed to advancing rigorous science that supports the emotional and psychological well-being of people living with cancer.

Click to read the full study: https://www.sunstonetherapies.com/research/long-term-psilocybin-benefits-research/

08/15/2025

Sunstone is hiring! Join us in establishing the gold-standard for safe, effective, and accessible psychedelic-assisted therapy within a medical setting.

To learn more and apply, visit: https://jobs.gusto.com/postings/sunstone-therapies-health-systems-operations-specialist-5a7481e8-c764-41c4-840d-b5b206ce453a

07/29/2025

In the evolving world of psychedelic-assisted therapy, one truth stands out: expectations shape experience. But what happens when those expectations lead to disappointment?

In our latest blog from The Modern Medicine Group on Psychology Today, Sunstone Therapist Dr. Mark Bates explores why naming potential disappointments in clinical trials—from screening out to subtle or overwhelming sessions—can actually enhance safety, trust, and healing.

Whether you're a participant, therapist, or researcher, embracing the full spectrum of outcomes opens the door to deeper integration and long-term growth.

Click here to read the full article:
https://www.sunstonetherapies.com/psychedelic-therapy-and-the-paradox-of-expectations/

07/24/2025

Missed our webinar on FDA-approved psychedelic clinical trials?
We’ve got you covered — the full conversation is now available to watch!

In this discussion, Dr. Manish Agrawal — Sunstone’s CEO and Principal Investigator — shares insights from his experience conducting psychedelic therapy research and responds to a range of participant questions. The session is a helpful resource for anyone interested in learning more about these clinical studies.

Watch the recording here: https://vimeo.com/1104267956/dac4a76d01?ts=0&share=copy

07/21/2025

Don't Miss Out – Our Webinar is Tomorrow!

There’s still time to register for our upcoming webinar on FDA-approved psychedelic-assisted therapy clinical trials, happening tomorrow!

Join Dr. Manish Agrawal, Sunstone’s CEO and Principal Investigator, as he shares insights from conducting psychedelic therapy research, discusses key considerations, and answers questions.

Let’s explore the future of mental health together!

Click here to register:
https://docs.google.com/forms/d/e/1FAIpQLSfzoET850xkWLBP9yGTSuPpnftA1y3mLael6aLsFtkUJHbVnw/viewform

07/17/2025

We're honored to see our most recent research highlighted in Oprah Daily—and even more grateful that it's reaching those who may benefit most.

The study, exploring psilocybin-assisted therapy for cancer patients experiencing depression, reflects years of work to bring compassionate, evidence-based care to those navigating the emotional weight of a cancer diagnosis. It investigates how a single dose of psilocybin, combined with skilled therapeutic support, can offer lasting relief from depression and anxiety—even in the midst of serious illness.

To see this work resonate beyond the academic world is a reminder of why we do what we do.

Read the article:
https://www.oprahdaily.com/life/health/a65336684/psilocybin-for-cancer-depression/

Explore Sunstone’s published psychedelic research and clinical trial results. Our studies include M**A therapy and psilocybin for depression and PTSD.

07/09/2025

Our Co-founder and CEO, Dr. Manish Agrawal, begins a new, four-part series of conversations with Pharmacy Times’ Lead Editor Alana Hippensteele examining the evolving role of psychedelic-assisted therapy, particularly for patients with cancer and those in palliative care.

In this first interview focused on Clinical Perspectives on Psychedelics in Palliative Oncology, Dr. Agrawal shares key insights from Sunstone’s recent research, addressing several important topics:

▪️ Emerging Therapeutic Approaches: Exploring innovative methods of therapy that are currently being researched for their potential to provide deeper psychological support.

▪️ Understanding What Matters: Discussing how researchers are working to truly understand the lasting positive impacts of these therapies.

▪️ Exploring Integration in Cancer Care: Insights into the growing interest and careful consideration of integrating psychedelics into cancer and palliative care.

Watch/Read the full interview: https://www.sunstonetherapies.com/advancing-psychedelic-assisted-therapy-insights-from-sunstones-latest-research-with-dr-manish-agrawal/?fbclid=fbclid

Stay tuned for the next interview in the series, where Dr. Agrawal discusses the expanding influence of Sunstone’s pioneering group-based psychedelic therapy model.

06/30/2025

Curious about FDA-approved psychedelic-assisted therapy clinical trials, or know someone who is? Join our webinar to get your questions answered and hear firsthand from Sunstone's CEO and Principal Investigator, Dr. Manish Agrawal. He'll discuss this innovative treatment and what's involved in a clinical trial.

Learn More & Register:

Join Dr. Agrawal as he shares vital insights into psychedelic medicine and clinical trials. Learn and ask questions about this treatment.

06/27/2025

Today is . We recognize the profound impact PTSD has on millions, including active and retired service members, and those affected by trauma. At Sunstone Therapies, we are dedicated to exploring innovative approaches, including psychedelic-assisted therapy, to bring hope and healing to individuals living with .